具体实施方式
下面将更详细地描述本发明的优选实施方式。虽然以下描述了本发明的优选实施方式,然而应该理解,可以以各种形式实现本发明而不应被这里阐述的实施方式所限制。
下述实施例中所述实验方法,如无特殊说明,均为有机合成与生物测试的常规方法;所述试剂和生物材料,如无特殊说明,均从商业途径获得。
实施例1化合物Y1的制备
实施例1A中间体2,4-二氯-6-甲氧基-喹啉-7-醇(式III所示化合物)
将5-氨基-2-甲氧基苯酚(式II所示化合物)(4.91g,35.29mmol)与丙二酸(7.34g,70.57mmol)加入到圆底烧瓶中,加入三氯氧磷(70ml),氮气保护下先室温搅拌反应4小时,之后加热到90℃反应过夜。旋除大部分三氯氧磷后,将所得油状物缓慢低价至冰水中,加入6M的NaOH调节pH至中性偏弱碱。继而以乙酸乙酯萃取得粗品,经柱色谱分离得纯品(2.98g,产率35%)。
化合物表征:1H NMR(400MHz,Chloroform-d)δ7.46(s,1H),7.40(s,1H),7.36(s,1H),4.10(s,3H).13C NMR(101MHz,CDCl3)δ150.46,148.55,147.91,145.51,142.26,120.51,119.66,111.07,101.62,56.41.
实施例1B 6-((2,4-二氯-6-甲氧基喹啉-7-基)氧)己酸乙酯(式IV所示化合物,n=1,R3=C2H5)
往圆底烧瓶中加入实施例1A所得化合物(1eq.)与溴代己酸乙酯(1.01eq.),加入DMF使原料溶解后,再加入碳酸铯(1.5eq.)作碱,室温下搅拌反应约5小时,点板监控至原料反应完全。反应结束后将反应液倒入水中,静置过滤得粗品,柱色谱分离后得纯品。
化合物表征:1H NMR(400MHz,Chloroform-d)δ7.37(s,1H),7.35(s,1H),7.33(s,1H),4.23–4.08(m,4H),4.04(s,3H),2.36(t,J=7.5Hz,2H),1.96(p,J=6.9Hz,2H),1.74(p,J=7.5Hz,2H),1.61–1.49(m,2H),1.27(t,J=7.2Hz,3H).13C NMR(101MHz,CDCl3)δ173.59,153.33,151.07,147.43,145.27,142.05,120.52,119.68,108.34,101.82,68.99,60.34,56.28,34.24,28.48,25.60,24.73,14.30.
实施例1C 6-((4-氯-6-甲氧基-2-(5-甲基呋喃-2-基)喹啉-7-基)氧)己酸乙酯(式V所示化合物,n=1,R1=2-甲基呋喃,R3=C2H5)
此步反应利用Suzuki反应完成,一般过程如下:将实例1B所得化合物(1eq.)溶于二氧六环和水的混合溶液中,加入碳酸钠(2eq.)、钯催化剂四三苯基膦钯(0.1eq.)以及相应的硼酸频那醇酯衍生物(2-甲基呋喃-5-硼酸频哪醇酯)(2eq.),80℃氮气保护封管反应2小时,点板监控至实例1B化合物反应完全。加入水和乙酸乙酯萃取,有机相以柱色谱分离得产品。
化合物表征:1H NMR(400MHz,Chloroform-d)δ7.72(s,1H),7.42(s,1H),7.36(s,1H),7.03(d,J=3.3Hz,1H),6.29–6.07(m,1H),4.26–4.11(m,4H),4.04(s,3H),2.45(s,3H),2.36(t,J=7.5Hz,2H),1.97(p,J=6.9Hz,2H),1.74(p,J=7.5Hz,2H),1.61–1.51(m,2H),1.27(t,J=7.1Hz,3H).13C NMR(101MHz,CDCl3)δ173.62,154.33,152.64,151.41,150.43,147.21,145.96,140.67,120.36,115.43,110.83,109.02,108.62,101.95,68.86,60.32,56.20,34.27,28.60,25.63,24.76,14.30,14.07.
实施例1D 6-((6-甲氧基-2-(5-甲基呋喃-2-基)-4-((1-甲基哌啶-4-基)氨基)喹啉-7-基)氧)己酸乙酯(式VI所示化合物,n=1,R1=2-甲基呋喃,R2=1-甲基哌啶;R3=C2H5)
本步反应通过Buchwald-Hartwig反应完成,将实施例1C所得化合物(1eq.)与过量的氨基衍生物(1-甲基-4-氨基哌啶)(10eq.)溶解于二氧六环中,以Pd2(dba)3(0.2eq.)为催化剂,以BINAP(0.4eq.)为配体,加入碳酸铯(5eq.)作碱,使用双排管抽真空后充氮气保护,100℃封管反应约20小时。或者使用(2'-二叔丁基膦-1,1'-联苯基-2-亚基)醋酸钯(II)(0.3eq.)作催化剂,以甲醇钠(2eq.)作碱,以甲苯为溶剂,80℃封管反应约20小时。加水和乙酸乙酯淬灭反应后有机相经柱色谱分离得油状产品,未继续纯化而直接用于后续反应。
实施例1E N-羟基-6-((4-氯-6-甲氧基-2-(5-甲基呋喃-2-基)喹啉-7-基)氧)己酰胺(Y1)(式I所示化合物,n=1,R1=2-甲基呋喃,R2=1-甲基哌啶)
本反应将实施例1D所得化合物的酯键转化为目标化合物的异羟肟酸官能团。首先将实施例1D所得化合物(1eq.)加入圆底烧瓶中,加入适量甲醇或二氯甲烷使之充分溶解,依次加入羟胺的水溶液(15.17M,5eq.)和甲醇钠的甲醇溶液(5M,10eq.),室温下搅拌反应,点板监控至原料反应完全。旋除反应液,加入适量水使固体溶解,滴加3M的盐酸调pH至中性,此时有白色沉淀产生。过滤并以乙醚、正己烷等洗涤滤饼得目标化合物。化合物表征如下:
Y1:1H NMR(400MHz,DMSO-d6)δ10.37(s,1H),8.72(s,1H),7.47(s,1H),7.11(s,1H),6.96(d,J=3.2Hz,1H),6.68(s,1H),6.52(d,J=7.8Hz,1H),6.21(d,J=3.2Hz,1H),4.04(t,J=6.5Hz,2H),3.88(s,3H),3.58–3.45(m,1H),2.83(d,J=10.9Hz,2H),2.36(s,3H),2.20(s,3H),2.11–2.02(m,2H),2.02–1.85(m,4H),1.83–1.70(m,2H),1.70–1.61(m,2H),1.61–1.49(m,2H),1.48–1.33(m,2H).13C NMR(101MHz,DMSO)δ169.53,153.53,152.67,151.38,148.95,148.01,147.70,145.63,112.39,109.55,109.41,108.73,102.03,93.02,68.37,56.67,55.07,49.62,46.55,32.74,31.90,28.83,25.74,25.40,14.13,0.61.HRMS(ESI)m/z C27H36N4O5,[M+H]+计算值497.2764,实测值497.2773。熔点143.8-145.3℃。
实施例2化合物Y2的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,DMSO-d6)δ10.39(s,1H),8.86(s,1H),7.48(s,1H),7.11(s,1H),7.02–6.79(m,2H),6.63(s,1H),6.21(s,1H),4.04(s,2H),3.87(s,3H),3.18(s,2H),2.90–2.66(m,2H),2.36(s,3H),2.12(s,3H),1.97(t,J=7.4Hz,2H),1.88–1.66(m,6H),1.62–1.48(m,2H),1.47–1.33(m,2H),1.32–1.18(m,2H).13C NMR(101MHz,DMSO)δ169.49,153.55,152.65,151.34,150.10,148.04,147.67,145.41,112.27,109.50,109.39,108.75,101.80,92.74,68.37,56.57,55.71,48.81,46.72,34.76,32.75,30.66,28.83,25.74,25.41,14.12.HRMS(ESI)m/z C28H38N4O5,[M+H]+计算值511.2920,实测值511.2924。熔点141.6-142.9℃。
实施例3化合物Y3的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,DMSO-d6)δ10.39(s,1H),8.75(s,1H),7.49(s,1H),7.12(s,1H),6.98(d,J=3.2Hz,1H),6.70(s,1H),6.52(d,J=7.8Hz,1H),6.23(d,J=3.1Hz,1H),4.05(t,J=6.6Hz,2H),3.89(s,3H),3.58–3.49(m,1H),2.85(d,J=11.0Hz,2H),2.79–2.68(m,1H),2.38(s,3H),2.34–2.23(m,2H),2.12–1.90(m,4H),1.86–1.70(m,2H),1.70–1.49(m,4H),1.49–1.34(m,2H),1.00(s,3H),0.99(s,3H).13C NMR(101MHz,DMSO)δ169.47,153.57,152.66,151.37,148.96,148.02,147.72,145.64,112.39,109.56,109.42,108.72,102.03,93.01,68.37,56.65,54.18,50.36,47.84,32.73,32.40,28.83,25.74,25.41,18.69,14.13.HRMS(ESI)m/z C29H40N4O5,[M+H]+计算值525.3077,实测值525.3073。熔点133.5-134.7℃。
实施例4化合物Y4的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,DMSO-d6)δ10.39(s,1H),8.74(s,1H),8.21–8.06(m,2H),7.53(s,1H),7.51–7.43(m,2H),7.43–7.37(m,1H),7.21(s,1H),6.89(s,1H),6.54(d,J=7.8Hz,1H),4.07(t,J=6.5Hz,2H),3.92(s,3H),3.77–3.59(m,1H),2.84(d,J=12.0Hz,2H),2.21(s,3H),2.16–2.06(m,2H),2.06–1.89(m,4H),1.85–1.74(m,2H),1.74–1.63(m,2H),1.63–1.51(m,2H),1.51–1.35(m,2H).13C NMR(101MHz,DMSO)δ169.50,155.03,151.35,149.36,148.24,145.72,141.00,128.82,127.31,112.55,109.87,101.84,95.10,68.39,56.67,55.07,49.45,46.59,32.75,31.95,28.87,25.76,25.42.HRMS(ESI)m/z C28H36N4O4,[M+H]+计算值493.2815,实测值493.2814。熔点175.9-177.4℃。
实施例5化合物Y5的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,DMSO-d6)δ10.33(s,1H),8.71(s,1H),7.48(s,1H),7.11(s,1H),6.95(d,J=3.2Hz,1H),6.68(s,1H),6.50(d,J=7.7Hz,1H),6.22(s,1H),4.05(t,J=6.6Hz,2H),3.89(s,3H),3.59–3.47(m,1H),2.83(d,J=11.1Hz,2H),2.36(s,3H),2.20(s,3H),2.15–2.02(m,2H),2.01–1.88(m,3H),1.84–1.72(m,2H),1.72–1.58(m,2H),1.58–1.46(m,2H),1.46–1.37(m,2H),1.37–1.25(m,2H).13C NMR(101MHz,DMSO)δ169.59,153.57,152.66,151.44,148.97,148.09,147.74,145.68,112.44,109.53,108.71,102.16,93.07,68.43,56.73,55.06,49.66,46.54,32.76,31.91,28.96,28.85,25.79,25.58,14.11.HRMS(ESI)m/z C28H38N4O5,[M+H]+计算值511.2920,实测值511.2924。熔点138.8-139.7℃。
实施例5化合物Y6的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,DMSO-d6)δ10.33(s,1H),8.67(s,1H),7.50(s,1H),7.13(s,1H),6.96(d,J=3.1Hz,1H),6.90(s,1H),6.65(s,1H),6.23(d,J=3.1Hz,1H),4.07(t,J=6.5Hz,2H),3.89(s,3H),3.23–3.16(m,2H),2.78(d,J=11.1Hz,2H),2.38(s,3H),2.26–2.18(m,1H),2.15(s,3H),2.00–1.92(m,1H),1.90–1.62(m,7H),1.59–1.49(m,2H),1.49–1.40(m,2H),1.40–1.21(m,4H).13C NMR(101MHz,DMSO)δ169.59,153.58,152.65,151.41,150.12,148.11,147.70,145.45,112.30,109.48,108.72,101.91,92.78,68.42,56.63,55.68,48.80,46.67,34.78,34.30,32.76,30.64,28.79,25.80,14.11.HRMS(ESI)m/z C29H40N4O5,[M+H]+计算值525.3077,实测值525.3073。熔点121.5-122.6℃。
实施例7化合物Y7的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,DMSO-d6)δ10.36(s,1H),8.70(s,1H),7.49(s,1H),7.12(s,1H),6.97(d,J=3.2Hz,1H),6.70(s,1H),6.51(d,J=7.8Hz,1H),6.23(s,1H),4.06(t,J=6.6Hz,2H),3.89(s,3H),3.61–3.47(m,1H),2.86(d,J=11.1Hz,2H),2.79–2.68(m,1H),2.38(s,3H),2.35–2.23(m,2H),2.04–1.92(m,3H),1.83–1.71(m,2H),1.71–1.55(m,2H),1.55–1.47(m,2H),1.47–1.38(m,2H),1.38–1.24(m,2H),1.01(s,3H),0.99(s,3H).13C NMR(101MHz,DMSO)δ169.59,153.57,152.66,151.40,148.96,148.04,147.72,145.65,112.38,109.55,109.43,108.72,102.05,93.00,68.40,56.67,54.19,50.35,47.85,32.75,32.41,28.96,28.84,25.79,25.58,18.70,14.14.HRMS(ESI)m/z C30H42N4O5,[M+H]+计算值539.3233,实测值539.3253。熔点116.4-117.3℃。
实施例8化合物Y8的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,DMSO-d6)δ10.33(s,1H),8.66(s,1H),7.48(s,1H),7.42–7.29(m,4H),7.26(d,J=4.5Hz,1H),7.12(s,1H),6.97(d,J=3.2Hz,1H),6.71(s,1H),6.50(d,J=7.8Hz,1H),6.22(d,J=3.1Hz,1H),4.06(t,J=6.6Hz,2H),3.90(s,3H),3.68–3.56(m,1H),3.53(s,2H),2.89(d,J=11.2Hz,2H),2.38(s,3H),2.25–2.11(m,2H),2.10–1.88(m,4H),1.86–1.73(m,2H),1.73–1.60(m,2H),1.59–1.48(m,2H),1.48–1.38(m,2H),1.38–1.25(m,2H).13C NMR(101MHz,DMSO)δ169.60,153.57,152.66,151.44,148.95,148.10,147.75,145.66,139.27,129.18,128.65,127.33,112.42,109.56,109.51,108.70,102.09,93.07,68.44,62.63,56.69,52.73,49.84,32.75,31.98,28.96,28.84,25.79,25.58,14.11.HRMS(ESI)m/z C34H42N4O5,[M+H]+计算值587.3233,实测值587.3209。熔点118.3-119.9℃。
实施例9化合物Y9的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,Acetone-d6)δ8.28–8.05(m,2H),7.54(s,1H),7.51–7.43(m,2H),7.43–7.36(m,1H),7.20(s,1H),6.89(s,1H),6.55(d,J=7.8Hz,1H),4.07(t,J=6.5Hz,2H),3.92(s,3H),3.74–3.62(m,1H),2.90–2.76(m,2H),2.21(s,3H),2.16–2.05(m,2H),2.05–1.88(m,4H),1.85–1.73(m,2H),1.73–1.60(m,2H),1.60–1.48(m,2H),1.48–1.39(m,2H),1.39–1.22(m,2H).13C NMR(101MHz,DMSO)δ169.52,155.03,151.37,149.36,148.26,145.72,141.00,128.82,127.31,112.55,109.86,101.86,95.10,68.41,56.68,55.07,49.45,46.58,32.77,31.94,29.00,28.87,25.82,25.61.HRMS(ESI)m/z C29H38N4O4,[M+H]+计算值507.2971,实测值507.2983。熔点152.1-153.6℃。
实施例10化合物Y10的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,DMSO-d6)δ10.35(s,1H),8.78(s,1H),7.49(s,1H),7.12(s,1H),6.97(d,J=3.2Hz,1H),6.70(s,1H),6.53(d,J=7.7Hz,1H),6.23(d,J=3.2Hz,1H),4.06(t,J=6.5Hz,2H),3.89(s,3H),3.59–3.47(m,1H),2.85(dd,J=9.2,5.7Hz,2H),2.38(s,3H),2.21(s,3H),2.16–2.03(m,2H),2.01–1.91(m,3H),1.85–1.72(m,2H),1.72–1.56(m,2H),1.57–1.46(m,2H),1.46–1.38(m,2H),1.38–1.12(m,4H).13C NMR(101MHz,DMSO)δ168.95,152.94,152.06,150.80,148.35,147.43,147.10,145.05,111.78,108.94,108.80,108.12,101.45,92.41,67.83,56.07,54.46,49.03,45.95,32.14,31.30,28.44,28.41,28.36,25.37,24.99,13.52.HRMS(ESI)m/z C29H40N4O5,[M+H]+计算值525.3077,实测值525.3087。熔点76.2-77.3℃。
实施例11化合物Y11的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,DMSO-d6)δ10.36(s,1H),8.72(s,1H),7.49(s,1H),7.13(s,1H),7.04–6.86(m,2H),6.65(s,1H),6.23(d,J=3.1Hz,1H),4.05(t,J=6.6Hz,2H),3.88(s,3H),3.19(t,J=6.1Hz,2H),2.84–2.71(m,2H),2.37(s,3H),2.13(s,3H),1.94(t,J=7.3Hz,2H),1.89–1.60(m,8H),1.58–1.13(m,12H).13CNMR(101MHz,DMSO)δ169.63,153.53,152.66,151.38,150.12,148.08,147.68,145.42,112.27,109.51,109.39,108.74,101.84,92.75,68.44,56.59,55.69,48.80,46.68,34.75,32.75,30.63,29.03,29.00,28.95,25.97,25.58,14.10.HRMS(ESI)m/z C30H42N4O5,[M+H]+计算值539.3233,实测值539.3251。熔点104.5-105.9℃。
实施例12化合物Y12的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,DMSO-d6)δ10.36(s,1H),8.72(s,1H),7.48(s,1H),7.12(s,1H),6.98(d,J=3.2Hz,1H),6.70(s,1H),6.53(d,J=7.8Hz,1H),6.23(d,J=3.2Hz,1H),4.05(t,J=6.6Hz,2H),3.89(s,3H),2.91–2.80(m,2H),2.80–2.68(m,1H),2.37(s,3H),2.35–2.25(m,2H),2.08–1.89(m,4H),1.80–1.70(m,2H),1.67–1.56(m,2H),1.54–1.45(m,2H),1.45–1.38(m,2H),1.38–1.30(m,2H),1.30–1.21(m,2H),1.00(s,3H),0.99(s,3H).13C NMR(101MHz,DMSO)δ169.64,153.52,152.68,151.40,148.98,148.04,147.71,145.63,112.37,109.59,109.37,108.73,102.02,93.01,68.44,56.66,54.20,50.35,47.83,32.75,32.35,29.02,28.95,25.96,25.57,18.67,14.13.HRMS(ESI)m/z C31H44N4O5,[M+H]+计算值553.3390,实测值553.3397。熔点111.1-112.2℃。
实施例13化合物Y13的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,DMSO-d6)δ10.36(s,1H),8.74(s,1H),8.27–7.99(m,2H),7.53(s,1H),7.50–7.43(m,2H),7.43–7.36(m,1H),7.20(d,J=1.9Hz,1H),6.88(s,1H),6.54(d,J=7.8Hz,1H),4.08(t,J=6.5Hz,2H),3.91(s,3H),3.73–3.61(m,1H),2.92–2.77(m,2H),2.21(s,3H),2.16–2.06(m,2H),2.05–1.91(m,3H),1.85–1.72(m,2H),1.72–1.59(m,2H),1.58–1.39(m,4H),1.39–1.21(m,4H).13C NMR(101MHz,DMSO)δ155.02,151.37,149.36,148.26,145.72,141.00,128.82,127.31,112.53,109.85,101.84,95.09,68.46,56.68,55.07,49.44,46.58,32.76,31.94,29.05,28.97,25.99,25.59.HRMS(ESI)m/z C30H40N4O4,[M+H]+计算值521.3128,实测值521.3134。熔点151.2-152.3℃。
实施例14化合物Y14的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,DMSO-d6)δ10.36(s,1H),8.72(s,1H),8.22–8.02(m,2H),7.54(s,1H),7.51–7.43(m,2H),7.43–7.36(m,1H),7.21(s,1H),6.97(t,J=5.7Hz,1H),6.83(s,1H),4.08(t,J=6.6Hz,2H),3.90(s,3H),3.28(t,J=6.2Hz,2H),2.84–2.69(m,2H),2.13(s,3H),1.95(t,J=7.3Hz,2H),1.88–1.64(m,7H),1.56–1.40(m,4H),1.38–1.20(m,6H).13C NMR(101MHz,DMSO)δ168.97,154.33,150.74,149.89,147.70,144.92,140.39,128.24,126.65,111.81,109.26,101.02,94.11,67.86,55.98,55.13,48.06,46.12,34.22,32.15,30.05,28.45,28.37,25.38,24.99.HRMS(ESI)m/z C31H42N4O4,[M+H]+计算值535.3284,实测值535.3302。熔点113.5-114.0℃。
实施例15化合物Y15的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,DMSO-d6)δ10.35(s,1H),8.71(s,1H),8.23–8.02(m,2H),7.53(s,1H),7.51–7.43(m,2H),7.43–7.36(m,1H),7.21(s,1H),6.90(s,1H),6.55(d,J=7.8Hz,1H),4.08(t,J=6.5Hz,2H),3.91(s,3H),3.78–3.62(m,1H),2.98–2.70(m,3H),2.46–2.25(m,2H),2.13–1.99(m,2H),1.99–1.86(m,2H),1.85–1.71(m,2H),1.71–1.57(m,2H),1.56–1.40(m,4H),1.39–1.31(m,2H),1.31–1.22(m,2H),1.02(s,3H),1.00(s,3H).13C NMR(101MHz,DMSO)δ169.00,154.38,150.78,148.77,147.67,145.07,140.34,128.22,126.71,111.90,109.20,101.24,94.49,67.86,56.07,53.70,49.51,47.21,32.16,31.74,28.45,28.37,25.39,24.98,18.02.HRMS(ESI)m/zC32H44N4O4,[M+H]+计算值549.3441,实测值549.3433。熔点111.7-112.9℃。
实施例16化合物Y16的制备
化合物制备方法参考实施例1。化合物表征如下:1H NMR(400MHz,DMSO-d6)δ10.36(s,1H),8.72(s,1H),8.24–8.03(m,2H),7.53(s,1H),7.50–7.43(m,2H),7.43–7.37(m,1H),7.36–7.29(m,4H),7.29–7.23(m,1H),7.20(s,1H),6.90(s,1H),6.54(d,J=7.9Hz,1H),4.07(t,J=6.6Hz,2H),3.91(s,3H),3.81–3.66(m,1H),3.52(s,2H),2.97–2.79(m,2H),2.26–2.11(m,2H),2.08–1.98(m,2H),1.98–1.88(m,2H),1.84–1.73(m,2H),1.73–1.60(m,2H),1.57–1.46(m,2H),1.46–1.39(m,2H),1.39–1.30(m,2H),1.30–1.18(m,2H).13C NMR(101MHz,DMSO)δ168.98,154.42,150.76,148.74,147.66,145.11,140.39,138.62,128.60,128.20,128.05,126.72,111.92,109.24,101.18,94.49,67.85,62.07,56.04,52.12,49.03,32.15,31.40,28.45,28.37,25.38,24.99.HRMS(ESI)m/z C36H44N4O4,[M+H]+计算值597.3441,实测值597.3467。熔点100.2-101.3℃。
实施例17
组蛋白去乙酰化酶抑制活性试验
以组蛋白去乙酰化酶家族的两个亚型HDAC1和HDAC6为研究对象,测试化合物对组蛋白去乙酰化酶的抑制活性,每个化合物设十个浓度梯度,三个复孔,并以已上市的HDAC抑制剂SAHA做对照。首先将化合物溶解到反应缓冲液中,之后加入一定体积的含组蛋白去乙酰化酶的缓冲溶液,室温孵育15分钟后加入胰蛋白酶和乙酰化的肽缓冲溶液作为反应底物以启动脱乙酰化反应,同时使化合物浓度和酶含量达到设定值,轻轻混合60秒后室温孵育,记录1个小时内一定激发光和发射光波长下反应的动力参数。通过和阴性对照组(无抑制剂组)比较得到化合物对酶的抑制活性,并计算得到化合物对组蛋白去乙酰化酶的半数抑制浓度(IC50),结果如表1所示。
实施例18
DNA甲基转移酶抑制活性试验
使用同位素标记的S-腺苷甲硫氨酸(3H-SAM)测试化合物对DNA甲基转移酶(DNMT1,DNMT3A,DNMT3B)的抑制活性,使用SAM的反应产物SAH做阳性对照。预先将化合物和相应的一定量的DNA甲基转移酶亚型混合,室温下孵育15min后,加入人工合成的生物素标记的寡核苷酸底物和3H-SAM并于室温下反应4h。接着将反应体系转移到链霉亲和素包被的高通量孔板中,室温反应1h。放射性活性通过液体闪烁计数法得到。通过和阴性对照组(无抑制剂组)比较得到化合物对酶的抑制活性,结果如表1所示。
表1化合物Y1-Y16酶抑制活性测试
注:*IC50,nM.
实施例19
MTT法细胞增殖抑制活性测试
测试了化合物在5μM浓度下处理结直肠癌细胞HCT116 72小时和48小时的肿瘤细胞增殖抑制活性,使用阳性化合物SGI1027(DNMT抑制剂)和SAHA(HDAC抑制剂)做对照。体外细胞增殖抑制实验采用MTT法,测试的具体步骤包括:
(a)样品准备:将化合物配制成5mM的DMSO溶液,并以DMSO梯度稀释得到相应浓度的样品溶液;
(b)铺板:取对数期细胞,通过血球计数板计数,将肿瘤细胞以每孔6-8×103个的密度接种于96孔板中,每孔培养基体积为99μL;
(c)加药:铺板后12-16h加药(待细胞贴壁后加药)。每孔加入1μL待测化合物溶液,使化合物终浓度为设定的浓度值,每个浓度设置4个复孔。同时设置两个阳性药组(分别加入HDAC抑制剂SAHA或DNMT抑制剂SGI-1027)和空白组(加入1μL DMSO);
(d)MTT处理:化合物与细胞共培养48h或72h后往实验组和对照组中加入MTT的PBS溶液(5mg/mL,10μL/孔),继续于培养箱中无菌培养4h;
(e)后处理与OD值测试:将96孔板离心并吸除培养基(贴壁细胞无须离心),加入DMSO(100μL/孔)并将96孔板在微量振荡器上振荡5分钟后使用酶标仪测试490nm处OD值,最后根据OD值计算出相应浓度下化合物对肿瘤细胞增殖的抑制率(Inh%)。
测试结果(表2)
表2化合物肿瘤细胞增殖抑制活性测试
由以上DNA甲基转移酶抑制活性测试、组蛋白去乙酰化酶抑制活性测试和肿瘤细胞增殖抑制活性测试的结果可以看出,本发明的式Ⅰ所示化合物对于DNA甲基转移酶和组蛋白去乙酰化酶具有良好的抑制活性,且可有效抑制肿瘤细胞增殖,可作为先导化合物用于抗肿瘤药物研发。
以上已经描述了本发明的各实施例,上述说明是示例性的,并非穷尽性的,并且也不限于所披露的各实施例。在不偏离所说明的各实施例的范围和精神的情况下,对于本技术领域的普通技术人员来说许多修改和变更都是显而易见的。